SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

Everything you need to know about the 2025 Java House Grand Prix of Monterey. Find race, driver, track and team information, as well as news and results.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to ...

The AAU Junior Olympics are right around the corner and the top high school athletes will be heading to Houston to compete. Here's how to watch everything.

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, Rallybio Corporation (NASDAQ:RLYB) announced a definitive agreement to ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...